FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

PURPOSE: Despite the progress that has been made in the treatment of mantle cell lymphoma (MCL), all patients invariably relapse with the currently available therapies. Because of the absence of curative therapy for MCL, we explored FTY720 as a novel agent against MCL. EXPERIMENTAL DESIGN: The cytot...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Liu, Qing, Alinari, Lapo, Chen, Ching-Shih, Yan, Fengting, Dalton, James T., Lapalombella, Rosa, Zhang, Xiaoli, Mani, Rajeswaran, Lin, Teresa, Byrd, John C., Baiocchi, Robert A., Muthusamy, Natarajan
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4180653/
https://ncbi.nlm.nih.gov/pubmed/20460491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2484
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars